The company has received final approval for its abbreviated new drug
application (ANDA) for Esomeprazole for oral suspension in the
strengths of 10mg, 20mg and 40mg from the United States Food and Drug
Administration (USFDA), Cipla said in a statement.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-gets-usfda-nod-for-generic-acid-reflux-drug/articleshow/74824762.cms
No comments:
Post a Comment